1. Home
  2. CRIS vs FAAS Comparison

CRIS vs FAAS Comparison

Compare CRIS & FAAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRIS
  • FAAS
  • Stock Information
  • Founded
  • CRIS 2000
  • FAAS 2021
  • Country
  • CRIS United States
  • FAAS Indonesia
  • Employees
  • CRIS N/A
  • FAAS N/A
  • Industry
  • CRIS Biotechnology: Biological Products (No Diagnostic Substances)
  • FAAS
  • Sector
  • CRIS Health Care
  • FAAS
  • Exchange
  • CRIS Nasdaq
  • FAAS NYSE
  • Market Cap
  • CRIS 32.8M
  • FAAS 34.6M
  • IPO Year
  • CRIS 2000
  • FAAS N/A
  • Fundamental
  • Price
  • CRIS $3.10
  • FAAS $0.58
  • Analyst Decision
  • CRIS Strong Buy
  • FAAS
  • Analyst Count
  • CRIS 3
  • FAAS 0
  • Target Price
  • CRIS $23.00
  • FAAS N/A
  • AVG Volume (30 Days)
  • CRIS 28.8K
  • FAAS 366.1K
  • Earning Date
  • CRIS 02-25-2025
  • FAAS 09-17-2024
  • Dividend Yield
  • CRIS N/A
  • FAAS N/A
  • EPS Growth
  • CRIS N/A
  • FAAS N/A
  • EPS
  • CRIS N/A
  • FAAS N/A
  • Revenue
  • CRIS $10,259,000.00
  • FAAS $57,730,593.00
  • Revenue This Year
  • CRIS N/A
  • FAAS N/A
  • Revenue Next Year
  • CRIS N/A
  • FAAS N/A
  • P/E Ratio
  • CRIS N/A
  • FAAS N/A
  • Revenue Growth
  • CRIS 0.44
  • FAAS 38.16
  • 52 Week Low
  • CRIS $2.86
  • FAAS $0.38
  • 52 Week High
  • CRIS $17.49
  • FAAS $12.97
  • Technical
  • Relative Strength Index (RSI)
  • CRIS 41.55
  • FAAS 47.80
  • Support Level
  • CRIS $3.10
  • FAAS $0.45
  • Resistance Level
  • CRIS $3.32
  • FAAS $0.67
  • Average True Range (ATR)
  • CRIS 0.18
  • FAAS 0.11
  • MACD
  • CRIS -0.01
  • FAAS 0.01
  • Stochastic Oscillator
  • CRIS 9.62
  • FAAS 35.65

About CRIS Curis Inc.

Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.

About FAAS DIGIASIA CORP

DigiAsia Corp operates as a holding company. The majority of DigiAsia's operations are currently conducted through its majority-owned entities, controlled entities and corporate joint venture. It is among the first embedded fintech as a service (EFaaS) companies in Indonesia serving business-to-business-to-consumer (B2B2C) customers, such as large corporations and state-owned enterprises, as well as business-to-business (B2B) customers, such as micro, small and medium-sized enterprise (MSME) merchants, across various segments. It aims to be a fintech-enabling platform in Southeast Asia by accelerating financial inclusion through its licenses and technology stack and combining the benefits of technological innovation with traditional financial services.

Share on Social Networks: